Larrea Biosciences to present scientific data at the International Congress on Natural Products Research (ICNPR) in Scottsdale, Arizona
Larrea Biosciences (NASDAQ symbol: LRRA) will be presenting data relating to safety and potential medical utility of products at the International Congress on Natural Products Research, which will be held in Scottsdale, Arizona from July 31st to August 4th, 2004. The Congress is a joint meeting of the American Society of Pharmacognosy, Association Francaise pour lÂ’Enseignement et la Recherche en Pharmacognosie, Gesellschaft fur Arzneipflanzenforschung, and the Phytochemical Society of Europe. The meeting will be attended by well over 1000 scientists, primarily from research institutions and the pharmaceutical industry.
Carson City, NV (PRWEB) July 28, 2004
Larrea Biosciences (NASDAQ symbol: LRRA) will be presenting data relating to safety and potential medical utility of products at the International Congress on Natural Products Research, which will be held in Scottsdale, Arizona from July 31st to August 4th, 2004. The Congress is a joint meeting of the American Society of Pharmacognosy, Association Francaise pour lÂ’Enseignement et la Recherche en Pharmacognosie, Gesellschaft fur Arzneipflanzenforschung, and the Phytochemical Society of Europe. The meeting will be attended by well over 1000 scientists, primarily from research institutions and the pharmaceutical industry.
The Larrea Biosciences presentations are entitled, “Safety Profile of Purified Larrea Tridentata Resin Extract Alone and in Combination with Ascorbic Acid” and “Utility of Purified Larrea Tridentata Leaf Resin Formulations for Viral and Inflammatory Conditions”. They represent a compilation of laboratory testing, clinical testing and consumer feedback from the period of 1996 to 2003. Some of this data has been cited in the Company’s four existing United States patents. The Company also has additional U. S. and international patents pending. Dr. Robert A. Sinnott, CTO of Larrea Biosciences, will be presenting the data to the scientific community along with Dr. W. Dennis Clark from the School of Life Sciences, Arizona State University.
The plant, Larrea tridentata, represents a large, untapped natural resource that has extensive commercial development opportunity. As well as the long history of medicinal use by Native Americans of the Southwestern U. S., the utility of the plant extract is substantiated by many years of modern scientific research, which supports utility as an important ingredient in health and consumer products.
About Larrea Biosciences Corporation
Larrea Biosciences Corporation is engaged in the industrial field of applied biosciences research and development. The Company also participates in the retail sector with worldwide distribution of nutriceutical and cosmeceutical products. The Company currently obtains the revenues from a patented ingredient, Virastatin, which is derived from the oldest living plant on earth, Larrea tridentata and a number of consumer products containing the ingredient. The ingredient and the products containing it are currently protected by four United States patents with additional U. S. and international patents pending. Virastatin-based products have demonstrated excellent results in treating herpes virus conditions, including cold sores, genital herpes and shingles; inflammatory conditions, including arthritis, sinusitis, gastrointestinal disorders, eczema, psoriasis; and various microbial and fungal conditions. The Company plans to become the world leader in the industrialization and commercialization of Larrea for a wide range of health and consumer products. Larrea Biosciences is currently involved in strategic partnership negotiations with several potential marketing and manufacturing partners.
Forward-Looking Statement
Any statements contained herein that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Potential factors could cause actual results to differ materially from those expressed or implied by such statements. Information on the potential factors that could affect the CompanyÂ’s actual results of operations is included in its filings with the Securities and Exchange Commission. These risks may be further discussed in periodic reports and registration statements to be filed by the Company from time to time with the Securities and Exchange Commission in the future.
# # #
